title: Withdrawal phenomena after atenolol and bopindolol: hormonal changes in normal volunteers.
abstract: 1. In order to observe and compare the withdrawal phenomena which follow treatment with the beta-adrenoceptor blocking drugs, bopindolol (with partial agonist activity PAA) and atenolol (without PAA), two groups of six normal volunteers were studied before, during and after 16 days drug administration. 2. Measurements of plasma levels of cortisol, prolactin, insulin, noradrenaline, adrenaline, glucose and potassium were made during a pre-treatment baseline period, on maximum dose and for 21 days after drug withdrawal. Isoprenaline infusions were given to determine sensitivity of heart rate responses and haemodynamic changes measured in response to physiological manoeuvres. 3. Following atenolol withdrawal the results show hormonal evidence of adrenergic overactivity in the form of elevation of plasma cortisol, insulin and glucose levels. After bopindolol withdrawal there was, in contrast, an overshoot of plasma prolactin and a persistent elevation of plasma potassium and adrenaline post-isoprenaline. 4. The hormonal changes which follow withdrawal of atenolol and bopindolol are associated with haemodynamic changes reported elsewhere (Walden et al., 1990). 5. These observations provide confirmatory evidence of a post beta-adrenoceptor blockade withdrawal syndrome which differs between the two drugs studied and this may reflect the properties of the drugs, in particular the PAA of bopindolol.
authors.affiliation: Clinical Pharmacology Department, University College, Middlesex School of Medicine, London.
authors.forename: R J
authors.initials: RJ
authors.lastname: Walden
authors.forename: B
authors.initials: B
authors.lastname: Tomlinson
authors.forename: B
authors.initials: B
authors.lastname: Graham
authors.forename: C
authors.initials: C
authors.lastname: Smith
authors.forename: D J
authors.initials: DJ
authors.lastname: Betteridge
authors.forename: B N
authors.initials: BN
authors.lastname: Prichard
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D001262:Atenolol / Q000009:adverse effects*; D001786:Blood Glucose / Q000032:analysis; D002395:Catecholamines / Q000097:blood; D005260:Female; D006728:Hormones / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007328:Insulin / Q000097:blood; D008297:Male; D010869:Pindolol / Q000009:adverse effects / Q000031:analogs & derivatives*; D011188:Potassium / Q000097:blood; D011388:Prolactin / Q000097:blood; D012016:Reference Values; D013375:Substance Withdrawal Syndrome / Q000097:blood*
chemical_list: D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D002395:Catecholamines; D006728:Hormones; D007328:Insulin; D001262:Atenolol; D011388:Prolactin; D010869:Pindolol; C036007:bopindolol; D011188:Potassium; D006854:Hydrocortisone